Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US investor adds diagnostic company to portfolio:

This article was originally published in Clinica

Executive Summary

Syngen Research, a US research company with proprietary diagnostic DNA amplification technologies, is to become part of the growing portfolio of Aethlon Medical. Aethlon, formerly Bishop Equities, is acquiring medical device technologies to commercialise on an international basis. Recently it gained Hemex, which has a blood purification technology device. In conjunction with a dialysis machine, the device, known as Hemopurifier, can remove targeted intoxicants such as iron, lead and aluminium from the blood. Future products in development include Hemopurifiers designed to remove certain viruses, plutonium and drug overdoses. Syngen and Aethlon are based in San Diego, California.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT079893

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel